Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer

Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer

Nov 30, 2020
|
staff reporter

NEW YORK – Verastem Oncology on Monday announced the launch of a Phase II clinical trial of its investigational MEK and pan-RAF inhibitor, VS-6766, as a treatment for recurrent, low-grade serous ovarian cancer patients, including those harboring KRAS mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Cancer

  1. Merck Nabs EU Keytruda Approval for MSI-High, Mismatch Repair Deficient Colorectal Cancer

  2. Cardiff Oncology to Begin Phase II Onvansertib Trial in Pancreatic Cancer

  3. Researchers ID Four Small Cell Lung Cancer Subtypes, Suggest Future Treatment Implications

    Premium

  4. MacroGenics' Margenza Improves PFS Over Herceptin in Phase III Breast Cancer Trial

  5. NeoGenomics to Grow Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.